Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04189250
Other study ID # COMP_aCO_oCO
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 20, 2020
Est. completion date August 1, 2020

Study information

Verified date March 2020
Source Swiss Federal Institute of Sport Magglingen
Contact Jon Wehrlin, Dr. scient., MSc.
Phone +41 58 467 61 25
Email jon.wehrlin@baspo.admin.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is the comparison of two measurement protocols determining hemoglobin mass with two different blood sampling strategies.Both protocols are based on the principle of the carbonmonoxid (CO) rebreathing method. During this measurement, CO is inhaled for a specific time period by the subject in a closed circuit and it is used as a marker to tag circulating hemoglobin.


Description:

The optimized CO rebreathing protocol (oCO) will be compared against the automatized CO rebreathing protocol (aCO). Although theses two protocols using the same method, they show some relevant differences.

The oCO use a 2 minutes rebreathing period in a seated position and capillary blood is taken. The aCO use a 10 minutes rebreathing period in a supine position and venous blood samples are taken.

It is essential to know to what extent the aCO with capillary or venous blood sampling with different rebreathing time and position compared to oCO will influence the provided hemoglobin mass values. It is important to ensure the comparability of formely hemoglobinmass data measured using oCO with hemoglobinmass data measured using aCO for scientific research.


Recruitment information / eligibility

Status Recruiting
Enrollment 31
Est. completion date August 1, 2020
Est. primary completion date April 20, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- age 18 or higher

- healthy (self-reported)

- women and men

Exclusion Criteria:

- smoker

- implementation of high altitude training six weeks before and during the study

- sickness before and during the study

- blood donation 6 weeks before and during the study

- pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Automatized carbonmonoxide rebreathing machine - OpCO Detalo instruments
The automatized protocol (aCO) will be conducted with automated system OpCO of Detalo instruments. The intended use of the OpCO Detalo instrument is to quantify hemoglobin mass in human. The principle behind the machine is the widely used CO rebreathing technique. The machine applies automatically the desired CO dose to the patient to determine hemoglobin mass. The Detalo Instruments OpCO is certified conform to the following CE norms: Electromagentic compabilitiy: DIN EN 60601-1-2 and electrical Safety test: LVD 2014/35/EU.

Locations

Country Name City State
Switzerland Swiss Federal Instistiution of Sport Magglingen

Sponsors (1)

Lead Sponsor Collaborator
Swiss Federal Institute of Sport Magglingen

Country where clinical trial is conducted

Switzerland, 

References & Publications (4)

Fagoni N, Breenfeldt Andersen A, Oberholzer L, Haider T, Meinild Lundby AK, Lundby C. Reliability and validity of non-invasive determined haemoglobin mass and blood volumes. Clin Physiol Funct Imaging. 2018 Mar;38(2):240-245. doi: 10.1111/cpf.12406. Epub 2017 Jan 30. — View Citation

Schmidt W, Prommer N. The optimised CO-rebreathing method: a new tool to determine total haemoglobin mass routinely. Eur J Appl Physiol. 2005 Dec;95(5-6):486-95. Epub 2005 Oct 13. — View Citation

Siebenmann C, Keiser S, Robach P, Lundby C. CORP: The assessment of total hemoglobin mass by carbon monoxide rebreathing. J Appl Physiol (1985). 2017 Sep 1;123(3):645-654. doi: 10.1152/japplphysiol.00185.2017. Epub 2017 Jun 29. Review. — View Citation

Steiner T, Wehrlin JP. Comparability of haemoglobin mass measured with different carbon monoxide-based rebreathing procedures and calculations. Scand J Clin Lab Invest. 2011 Feb;71(1):19-29. doi: 10.3109/00365513.2010.534174. Epub 2010 Nov 23. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of two CO rebreathing protocols (aCO and oCO) The aim is to assess the confidence interval of aCO with a ten min rebreathing period in supine position compared to oCO with a two min seated rebreathing period. The mean difference in hemoglobin mass will be determined, using the aCO and oCO. During data collection (3 months)
Primary Comparison of capillary and venous bloodsampling The aim is to compare capillary and venous blood samples collected simultaneously during aCO. The goal is to determine, if the site of blood sampling alters the measured carboxy-hemoglobin and hence the calculated hemoglobin mass.
The outcome will be the confidence interval of mean difference measured with capillary and venous blood sampling.
During data collection (3 months)
Secondary Reliability of aCO and oCO The aim is the determination of the reliability of aCO and oCO by implementing double measurements for both protocols. The coefficient of variation (CV) of hemoglobin mass measured for aCO and oCO will be a further outcome of the study. During data collection (3 months)
See also
  Status Clinical Trial Phase
Completed NCT03816514 - Noninvasive Hemoglobin Monitoring for Maintaining Hemoglobin Concentration Within the Target Range N/A
Completed NCT02722759 - Haemoglobin Measurement for Babies N/A
Completed NCT01529502 - Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting Phase 2
Terminated NCT00228995 - A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia Phase 2
Terminated NCT00210795 - A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia Phase 2
Completed NCT04869319 - Electronic Triggers: Messaging After A1C EHR Alert
Completed NCT02876627 - Effect Aerobic Training on Women With Breast Cancer After Chemotherapy Phase 1
Completed NCT02655107 - Non-invasive Measurement of Hemoglobin in Infants and Neonates N/A
Terminated NCT00246597 - A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer Phase 3
Completed NCT05506748 - Association Between Preoperative HALP and Immediate Postoperative Outcomes